News

CURE

FDA Grants Designation to Investigational Drug for Head and Neck Cancer

The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck ...

FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted ...
Targeted Oncology

Novel ADC Earns FDA Fast Track in Head and Neck Cancer

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

Corbus higher as FDA issues another fast track tag for lead asset

Corbus Pharmaceuticals (NASDAQ:CRBP) traded ~10% higher on Tuesday after the U.S. Food and Drug Administration (FDA) granted another Fast Track designation for the cancer drug developer’s lead asset, ...